


Stimulation of the prelimbic via optogenetics, produces a network effect, widespread throughout the brain



Transcranial Magnetic Stimulation (TMS)



History of Transcranial Magnetic Stimulation (TMS)






= TMS

Scribonius Largus 43 AD


History of Transcranial Magnetic Stimulation (TMS)





= TMS

Scribonius Largus 43 AD




From Horvath et al., 2011

Do rat and human PFC have anything in common?





Do rat and human PFC have anything in common?





Rat Prelimbic Area and Human/Monkey DL PFC share functional roles


■ The prelimbic area in rats and dIPFC in human/monkey are implicated in "executive functions"

<u>Inhibitory control</u> in rats (Jonkman et al 2009; Moorman and Aston-Jones, 2015) and self-control in humans (Hare et al 2009) are mediated by the prelimbic cortex and dIPFC, respectively

- Executive functions include:
 - Working memory
 - Temporal processing
 - Behavioral flexibility
 - Decision Making
- The Prelimbic/Infralimbic region in rats and dorsal and ventral lateral PFC in monkeys and humans support working memory for objects and places, temporal order for object and places, reversal learning, delay discounting and uncertainty-decision making (Kesner et al. 2011)

Stimulation of the DL PFC via rTMS, produces a widespread network effect

Human



From optogenetics to the clinic





-Site:

- Addiction Center, Padova, Italy
- Luigi Gallimberti MD and Alberto Terraneo PhD
- Outpatient Clinic setting

-Population:

- Female and male patients with cocaine use disorder
- Treatment-seekers for cocaine use disorder
- "Guardian" assigned to each patient

Treatment:

- -General medical management provided by addiction specialist physicians and other health care providers
- Assessment of adverse events, urine drug tests (UDTs), craving for cocaine, medical history, physical exam, psychological assessments (SCL-90-R)
- While AUD was exclusionary, patients were asked to abstain completely from any alcohol use during the duration of the study: disulfiram 400mg/day was used to assure compliance

Treatment:

Table 2 Participant characteristics at baseline $[M \pm (SD)]$ or percentage (%)].

	rTMS group (n=16)	Control group $(n=16)$
Age*	43.50 (9.75)	37.06 (5.95)
Women (N)	2	0
Race: Caucasians (%)	100	100
Age of first cocaine use	26.69 (9.34)	24.06 (6.23)
Years of cocaine use	16.81 (7.95)	13.00 (5.55)
Cocaine use during the last month (days per week)	4.81 (1.94)	4.31 (2.02)
Cocaine use during the last month (grams per day)	1.81 (1.11)	1.75 (0.77)
Tobacco smokers (%)	62.5%	56.25%
Last use		
Less than 24 h	37.50%	43.75%
Between 24 and 48 h	18.75%	25.00%
More than 48 h	43.75%	31.25%

^{*}p<0.05; unless otherwise noted, there were no significant differences between the groups on these measures [p>0.05]

Treatment:

-rTMS:

- Dorsolateral Prefrontal Cortex (MNI coordinates, left side)
- 15 Hz frequency, 60 pulses, 40 sec intervals (13 minutes per session)
- Duration of treatment:
 - ❖ Week 1: once a day for 5 consecutive days
 - ❖ Weeks 2-4: twice a week

-Primary aims:

- Assess SAFETY of the use of rTMS in a population of patients with cocaine use disorder
- •Assess FEASIBILITY of the use of rTMS in this population

-Primary aims:

- Assess SAFETY of the use of rTMS in a population of patients with cocaine use disorder
- •Assess FEASIBILITY of the use of rTMS in this population

-Secondary aim:

• Explore signal for efficacy to inform fully-powered controlled trials by comparing the experimental group to a control group via a randomized openlabel design

Cocaine Patients N = 32Control Group (n = 16) (they also received medications, e.g. benzodiazepines, bupropion) No serious or unanticipated side-effects 13 (81%) participants completed treatment All cocaine-negative UDTs: 3 (19%)*



Cocaine Patients N = 32

Experimental Group (n = 16) rTMS (and no medications)

Control Group (n = 16)

(they also received medications, e.g. benzodiazepines, bupropion)

- ☐ No serious or unanticipated side-effects
- 16 (100%) participants completed treatment
- ☐ All cocaine-negative UDTs: 11 (69%)*

- No serious or unanticipated side-effects
- ☐ 13 (81%) participants completed treatment
- ☐ All cocaine-negative UDTs: 3 (19%)*

*p = .0035; OR = 6.47

Urines monitored twice a week in both groups

Terraneo et al., 2015



Cocaine Patients N = 32

Experimental Group (n = 16) rTMS

(and no medications)

Control Group (n = 16)

(they also received medications, e.g. benzodiazepines, bupropion)

- No serious or unanticipated side-effects
- 16 (100%) participants completed treatment
- All cocaine-negative UDTs: 11 (69%)*


- No serious or unanticipated side-effects
- ☐ 13 (81%) participants completed treatment
- ☐ All cocaine-negative UDTs: 3 (19%)*

*p = .0035; OR = 6.47


10 out of 16 patients from the control arm went into rTMS treatment with statistically similar results to the rTMS group (7 out of 10 UDT negative)


Terraneo et al., 2015


Proportion of cocaine free patients is significantly higher in rTMS compared to control group



Craving score is significantly reduced in rTMS group










Urines and patients monitored every two weeks for the first 6 months
Then once a month

Number of stimulation per month after rTMS protocol






1. Computing TMS E-fields




Treatment Atlas: First Results (N=15)

TMS E-fields

Therapeutic atlas





- MNI coordinates versus foci of stimulation
- Importance of realistically shaped volume conductor model
- Building a probabilistic treatment atlas

Current plans and objectives

- Relationship between locus of stimulation and effectiveness
- Brain regions involved
- Standardization of rTMS protocol(s) versus "personalized" rTMS







Luigi Gallimberti Padova/Venice Lorenzo Leggio NIAAA/NIDA Alberto Terraneo Padova/Venice



Tommi Raij (Northwestern U)



Aapo Nummenmaa Mass Gen Hospital



Elliot Stein NIDA




Yihong Yang NIDA

Conclusions

- 1. Optogenetic based-rTMS study. Its rationale is based on the demonstration of a causal role of the prelimbic cortex in bidirectionally shaping cocaine seeking and taking.
- 2. It provides the first clear evidence supporting the SAFETY of rTMS in cocaine-addicted patients and suggest its potential therapeutic role for rTMS-driven prefrontal cortex (PFC) stimulation in reducing cocaine use.
- 3. It provides preliminary clinical evidence for rTMS efficacy in treating cocaine use disorders in patients.
- 4. It provides a strong rationale for developing larger placebo-controlled studies and create standardized rTMS treatment.
- 5. 99% of work still to be done

The Future of Neuroscience



The Future of Neuroscience



Acknowledgements

Lab Members



Mark Ungless (ICL)

Stephanie Borgland (UBC)

Garret Stuber (UNC)

Billy Chen (VC)

Current

Marco Pignatelli

Ross McDevitt

Hideaki Kano

Lindsay De Biase

Nick Edwards

Nathan Marchant

Hau-Jie Yau

Hugo Tejeda

Hui Shen

Sissi Ribeiro

Zach Fusfeld

Wendy Xin

Isobel Hawes

Rosa Anna Marino

Collaborations

Extramural

Karl Deisseroth

Thorase project

Ted Dawson

Valina Dawson

George Umanah

Glia project

Dwight Bergles

David Goldman

Kornel Schuebel

Kam Wing Jair

Raffaello Cimbro

Tim Liu

Haiying Zhang

Nigel Greig

rTMS team

Luigi Gallimberti

Alberto Terraneo

Tommi Raij

Elliot Stein

Yihong Yang

Lorenzo Leggio

Intramural

Yeka Aponte

Jean Lud Cadet

Sergi Ferre

Eliot Gardner

Brandon Harvey

Bruce Hope

Satoshi Ikemoto

Da-Ting Lin

Carl Lupica

Marisela Morales

Geoff Schoenbaum

Yavin Shaham

Roy Wise

Zheng-Xiong Xi

Thanks to NIDA and State of California